Windlas Biotech Limited (NSE:WINDLAS)

Market Cap	16.49B
Revenue (ttm)	8.30B
Net Income (ttm)	673.21M
Shares Out	20.96M
EPS (ttm)	31.73
PE Ratio	24.79
Forward PE	n/a
Dividend	5.80 (0.72%)
Ex-Dividend Date	Jul 21, 2025

Volume	21,714
Average Volume	41,542
Open	802.25
Previous Close	803.55
Day's Range	781.25 - 810.90
52-Week Range	665.10 - 1,140.00
Beta	0.24
RSI	51.82
Earnings Date	Nov 6, 2025

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophiliz...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,346
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WINDLAS

Financial Performance

In 2024, Windlas Biotech's revenue was 7.60 billion, an increase of 20.43% compared to the previous year's 6.31 billion. Earnings were 609.94 million, an increase of 4.82%.